Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Read about Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Read about Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Read about Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
DOI: 10.1126/scitranslmed.adn5651
Read about Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
DOI: 10.1126/sciimmunol.ads1328
Read about Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.
DOI: 10.1038/s41551-025-01399-4
Read about Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.
Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Read about Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Musunuru et. al (2025) “Patient-specific in vivo gene editing to treat a rare genetic disease” The New England Journal of Medicine.
DOI: 10.1056/NEJMoa2504747
Read about Musunuru et. al (2025) “Patient-specific in vivo gene editing to treat a rare genetic disease” The New England Journal of Medicine.
Kissling et al. (2025) “Predicting adenine base editing efficiencies in different cellular contexts by deep learning” Genome Biology.
DOI: 10.1186/s13059-025-03586-7
Read about Kissling et al. (2025) “Predicting adenine base editing efficiencies in different cellular contexts by deep learning” Genome Biology.
Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Read about Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
Read about Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025